• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

    1.760 +0.130 (+7.98%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,846,057
    Open 1.650
    Bid (Size) 1.660 (500)
    Ask (Size) 1.750 (400)
    Prev. Close 1.630
    Today's Range 1.600 - 1.760
    52wk Range 0.2425 - 2.010
    Shares Outstanding 70,417,345
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
    From Ovid Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +0.6%
    +0.6%
    1 Month
    +11.4%
    +11.4%
    3 Month
    -4.3%
    -4.3%
    6 Month
    +370.6%
    +370.6%
    1 Year
    +83.7%
    +83.7%

    More News

    Read More
    News headline image
    This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga
    News headline image
    OVID THERAPEUTICS INC (NASDAQ:OVID) Announces Leadership Transition and Key Pipeline Milestones Following Q3 2025 Results ↗
    Via Chartmill
    News headline image
    Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    These stocks that are showing activity before the opening bell on Friday. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Top movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Ovid Therapeutics Inc. - Common Stock publicly traded?
    Yes, Ovid Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Ovid Therapeutics Inc. - Common Stock trade on?
    Ovid Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ovid Therapeutics Inc. - Common Stock?
    The ticker symbol for Ovid Therapeutics Inc. - Common Stock is OVID on the Nasdaq Stock Market
    What is the current price of Ovid Therapeutics Inc. - Common Stock?
    The current price of Ovid Therapeutics Inc. - Common Stock is 1.760
    When was Ovid Therapeutics Inc. - Common Stock last traded?
    The last trade of Ovid Therapeutics Inc. - Common Stock was at 01/02/26 04:00 PM ET
    What is the market capitalization of Ovid Therapeutics Inc. - Common Stock?
    The market capitalization of Ovid Therapeutics Inc. - Common Stock is 123.93M
    How many shares of Ovid Therapeutics Inc. - Common Stock are outstanding?
    Ovid Therapeutics Inc. - Common Stock has 124M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.